Overview

A Clinical Study Evaluating the Use of HLX10 in Combination With HLX04 for the Treatment of Advanced Hepatocellular Carcinoma (HCC) Patients

Status:
Active, not recruiting

Trial end date:
2022-06-15

Target enrollment:

Participant gender:

Summary

This trial is a single-arm, open, multicenter phase II clinical study.Subjects can only enter this study after they meet the inclusion and exclusion criteria.Into subjects will accept HLX10 + HLX04 intravenous infusion, every two weeks, lose treatment until clinical benefit, toxicity, the subjects of the resistance or the doctor decided to suspend the treatment, tested subjects death revocation of informed consent, subjects, subjects of pregnancy, not to plan or program requirement from, or management reasons, treatment for up to 2 years (before).

Phase:

Phase 2

Details

Lead Sponsor:

Shanghai Henlius Biotech

Treatments:

Antibodies, Monoclonal
Bevacizumab